GLPwatch
Effect of Liraglutide on the Beta-cell Responsiveness in Subjects With Type 2 Diabetes Compared to a Healthy Control Group
NCT01511185 · Completed
Last updated 2026-05-28This clinical trial tested the effects of the medication liraglutide on insulin production in people with type 2 diabetes compared to healthy individuals.
Status Completed The study has finished.
Phase Phase 1 Checks safety and dosing in a small group.
Type Interventional (clinical trial)
Design Randomized, double-blind treatment study
Participants 20 people
Who can join Ages 18–75 · all sexes
Timeline Started 2001-02 · est. completion 2001-10
Where 1 site · United States
What this study is testing ClinicalTrials.gov NCT01511185 ↗
Description as written by the study sponsor.
This trial is conducted in the United States of America (USA). The aim of this trial is to assess the effect of NNC 90-1170 on beta-cell responsiveness to increasing blood glucose concentrations in subjects with type 2 diabetes.
Treatments tested
- liraglutide also known as NNC 90-1170 Drug
A single dose of 7.5 mcg/kg administered subcutaneously in random order
- placebo Drug
A single dose administered subcutaneously in random order
| Main thing measured | AUC (area under the curve) of Insulin Secretion Rate (ISR) over the 90-216 mg/dL glucose interval |
|---|---|
| Sponsor | Novo Nordisk A/S |
| Conditions studied | Diabetes, Diabetes Mellitus, Type 2 |
| GLP-1 drugs | liraglutide |
Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT01511185 ↗